Are there robust clinical data on the safety of IV amiodarone for atrial fibrillation of unclear duration and very difficult to control HR in the current era of widespread DOAC use, as opposed to older data with warfarin? 

In the current DOAC era, there are no prospective or randomized data specifically evaluating IV amiodarone administered for rate control in atrial fibrillation of uncertain duration. The principal safety concern is not the agent itself but the possibility of unintended pharmacologic cardioversion, w...